Crossmark

Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients

Crossref DOI link: https://doi.org/10.1186/s12885-018-4822-7

Published Online: 2018-09-21

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Ruo-Xi

Chen, Sheng http://orcid.org/0000-0003-3530-1287
Huang, Liang

Shao, Zhi-Ming
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81302298)

Natural Science Foundation of Shanghai (17ZR1405900)

shanghai sailing program (18YF1405000)
License Information

Text and Data Mining valid from 2018-09-21
More Information

Article History

Received: 18 January 2018

Accepted: 14 September 2018

First Online: 21 September 2018

Ethics approval and consent to participate

: Our study was approved by the independent ethical committee/institutional review board of Fudan University Shanghai Cancer Center (Shanghai Cancer Center Ethical Committee). All patients gave their written informed consent before inclusion in this study.

: NA

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.